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Abstract
Background: Idiopathic normal pressure hydrocephalus (iNPH) is a treatable neurological syndrome in the elderly.
Although the magnetic resonance imaging (MRI) findings of tight high-convexity and medial subarachnoid spaces
and the ventriculo-peritoneal (VP) shunt with programmable valve are reportedly useful for diagnosis and
treatment, respectively, their clinical significance remains to be validated. We conducted a multicenter prospective
study (Study of Idiopathic Normal Pressure Hydrocephalus on Neurological Improvement: SINPHONI) to evaluate
the utility of the MRI-based diagnosis for determining the 1-year outcome after VP shunt with the Codman-Hakim
programmable valve.
Methods: Twenty-six centers in Japan were involved in this study. Patients aged between 60 and 85 years with
one or more of symptoms (gait, cognitive, and urinary problems) and MRI evidence of ventriculomegaly and tight
high-convexity and medial subarachnoid spaces received VP shunt using the height/weight-based valve pressure-
setting scheme. The primary endpoint was a favorable outcome (improvement of one level or more on the
modified Rankin Scale: mRS) at one year after surgery, and the secondary endpoints included improvement of one
point or more on the total score of the iNPH grading scale. Shunt responder was defined by more than one level
on mRS at any evaluation point in one year.
Results: The full analysis set included 100 patients. A favorable outcome was achieved in 69.0% and 80.0% were
shunt responders. When measured with the iNPH grading scale, the one-year improvement rate was 77.0%, and
response to the surgery at any evaluation point was detected in 89.0%. Serious adverse events were recorded in
15 patients, three of which were events related to surgery or VP shunt. Subdural effusion and orthostatic headache
were reported as non-serious shunt-related adverse events, which were well controlled with readjustment of
pressure.
Conclusions: The MRI-based diagnostic scheme is highly useful. Tight high-convexity and medial subarachnoid
spaces, and enlarged Sylvian fissures with ventriculomegaly, defined as disproportionately enlarged subarachnoid-
space hydrocephalus (DESH), are worthwhile for the diagnosis of iNPH. This study is registered with ClinicalTrials.
gov, number NCT00221091.
Background
Normal-pressure hydrocephalus (NPH) is well known as
a treatable syndrome of the classical triad of gait distur-
bance, dementia, and urinary disturbance [1], and can
be classified into idiopathic NPH (iNPH) and secondary
NPH [2]. It develops in elderly people, and the rapid
increase in the number of elderly people among the
general population in Japan prompted the Japanese
Society of Normal Pressure Hydrocephalus to formulate
clinical guidelines for iNPH[ 3 , 4 ] .T h eJ a p a n e s eG u i d e -
lines were published in 2004 in Japanese [3], and the
English version of them was published in 2008 [4], and
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agement of iNPH have now also been published [5-9].
These guidelines played an important role in making
more widely known the diagnosis and management of
iNPH. However, there remain unanswered questions in
relation to both the diagnosis and treatment of iNPH.
Although tightness of high-convexity and medial sub-
arachnoid spaces, which is most appreciable on coronal
MRI sections, is reportedly a characteristic feature of
iNPH [10] and is recommended as a supportive sign of
the condition in the Japanese guidelines, its diagnostic
value remains to be validated in a large number of sus-
pected iNPH patients. Furthermore, although ventri-
culo-peritoneal (VP) shunt with a programmable valve is
recommended for treating hydrocephalus in general
[11,12], and for treating iNPH in the Japanese guidelines
[3,4], the outcome of iNPH patients who received VP
shunt with a programmable valve remains to be deter-
mined [13]. We conducted a multicenter prospective
study (Study of Idiopathic Normal Pressure Hydroce-
phalus on Neurological Improvement: SINPHONI) to
evaluate the utility of the MRI-based diagnosis for deter-
mining outcome 1-year after VP shunt with Codman-
Hakim programmable valve (CHPV). Herein, we report
the general profile of SINPHONI and its primary
findings.
Methods
Study design
The study was a multicenter prospective cohort study
conducted in compliance with the Guidelines for Good
Clinical Practice and the Declaration of Helsinki (2002)
of the World Medical Association. The study protocol
was approved by the institutional review board at each
site, and all patients (or their representatives when
applicable) gave written informed consent for participa-
tion. Twenty-six centers in Japan were involved in this
study (see Acknowledgement). The first patient was
recruited on November 8, 2004, and the follow-up of
the last patient was completed on December 28, 2006.
The Translational Research Informatics Center (TRI-
Kobe, Japan) together with the steering committee,
monitored all the clinical data, imaging data, data
related to safety issues, and protocol compliance via the
web-based case report system. This study is registered
with ClinicalTrials.gov, number NCT00221091.
Participants and protocol
The candidates for this studyw e r ep a t i e n t sw i t hs u s -
pected iNPH. After obtaining written informed consent,
t h ee l i g i b l ep a t i e n t sw e r ep r e - r e g i s t e r e da n dr e c e i v e d
lumbar puncture. The inclusi o nc r i t e r i aw e r e( 1 )a g e
between 60 and 85 years, (2) presence of one or more
symptom(s) of the triad (gait disturbance, cognitive
impairment, and urinary symptoms), which were mea-
surable on the iNPH Grading Scale (iNPHGS) [14], (3)
MRI features of iNPH, i.e., both ventriculomegaly of
Evans’ index > 0.3 and tight high-convexity and medial
subarachnoid spaces on coronal T1-weighted MRI (Fig-
ure 1) [10], (4) absence of known disorders causing ven-
triculomegaly, and (5) normal cerebrospinal fluid (CSF)
content (protein ≤ 50 mg/dl and cell count ≤3 μm
3) and
pressure (≤ 20 cmH2O). Exclusion criteria were (1) pre-
sence of musculoskeletal, cardiopulmonary, renal, hepa-
tic, or mental disorders that would make it difficult to
evaluate changes of symptoms, (2) obstacles to one-year
follow-up, and (3) hemorrhagic diathesis or anticoagu-
lant medication. For the evaluation of the MRIs, Evans’
index, size of the Sylvian fissures rated according to the
protocol of Kitagaki et al. [10], presence or absence of
Figure 1 Typical iNPH findings on MRI. Illustrative coronal sections of coronal T1-weighted images selected from an included patient showing
enlarged ventricles (*), tight high-convexity and medial surface subarachnoid spaces (oval ring), and expanded Sylvian fissures (arrow).
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changes according to scale of Fazekas et al. [15], were
assessed on each site and recorded.
The candidates were pre-registered before CSF exami-
nation via a web-based case report system. MRI was
reviewed by each site in the pre-registration phase, and
the final eligibility of the subjects was judged by the
central MRI review committee, which consist of neuro-
surgeons, neurologists, and a neuroradiologist. The cen-
tral MRI review committee excluded those whose MRI
did not fulfil the inclusion criteria. After the confirma-
tion of normal CSF content and pressure, the investiga-
tor was notified of registration via the web system. Tap
test was carried out in all subjects with 30 ml CSF
removal via lumbar puncture. CT cisternography was
carried out 1 week after the tap test with iohexol
(Omnipaque®: 180 mg/ml) 30 mg/kg. Cerebral blood
flow was measured using
123I-Iodoamphetamine and
single photon emission computed tomography at base-
line. However, the results of these measures were not
considered for the eligibility.
Outcome measures
The primary endpoint was improvement of one level or
more on the modified Rankin Scale (mRS) [16] at one
year after surgery (favorable outcome). The secondary
outcome measures included the iNPHGS [14], timed 3
meter “Up & Go” test (TUG) [17], and the Mini-Mental
State Examination (MMSE) [18]. The follow-up also
included CT scan. These measures were repeated at
baseline and at 3, 6, and 12 months after shunt surgery.
A positive response to VP shunt (shunt responder) was
defined as improvement by more than 1 level on mRS
at any evaluation point in one year.
VP shunt was carried out under general anesthesia
using a shunt system with CHPV. The initial pressure
for the shunt system was set before surgery according to
a standardized scheme, in which the initial pressure set-
ting was calculated from the patients’ height and body
mass index based on the estimated hydrostatic pressure
and intra-abdominal pressure [19,20]. The valve pres-
sure was readjusted by 1-3 cmH2O interval afterward as
required. Shunt function was assessed at each site when-
ever needed. If a surgical intervention was made to
repair the shunt, adverse event report was required as
described below. Safety assessments included the record-
ing of all adverse events throughout the study, irrespec-
tive of whether or not they were suspected to bear any
relation to treatment. A serious adverse event (SAE) was
defined as one of the followings: (1) death, (2) an event
that could result in death, (3) an event for which treat-
ment requires hospitalization or admittance to a clinic
or an extension of the hospitalization period, and (4) an
event that could result in morbidity.
Statistical analysis
To detect a 50% rate for favorable outcome, which was
considered as a clinically meaningful benefit, with a 95%
confidence interval (CI) of 40-60%, it was calculated that
97 patients are necessary. Therefore, to allow for any
withdrawals from the study, the sample size was set at
110. Analyses were based on the full analysis set. Where
there was missing data at any follow-up time point, data
was imputed using the “last observation carried for-
ward”. When no follow-up data was available, the maxi-
mally unfavorable score was allocated. The changes
from baseline to one year post-surgery were analyzed on
the mRS, iNPHGS, TUG, and MMSE using Wilcoxon
test in terms of total subjects, and subgroups with
favourable and unfavourable outcome. Descriptive statis-
tics were expressed as the mean and standard deviation
(SD) or as the median and 25-75 percentile interval.
Results
Trial profile
The flow chart for this study is shown in Figure 2. Pre-
registration was completed for 136 patients. After lum-
bar puncture, 15 patients were withdrawn because of
failure to fulfil the CSF inclusion criteria. Four patients
withdrew their consent between the pre-registration and
registration. Thus, 117 patients proceeded to the regis-
tration. At this stage, the central MRI review committee
excluded ten patients because of deviation from the
MRI criteria: eight patients lacked tight high-convexity
and medial subarachnoid spaces (Figure 3) and two
patients had intracranial mass lesions. Six patients who
Figure 2 Trial profile showing flow chart of patient numbers
from initial screening to final analysis.
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pulmonary tuberculosis did not receive surgery. Thus,
the full analysis set comprised the remaining 100
patients. Ten patients failed to receive one-year final fol-
low-up (death: 2, cerebral infarction: 1, myocardial
infarction: 1, femoral fracture: 1, and lost or withdrawal
of consent: 5), so that the follow-up completion rate
was 90%.
Patients’ characteristics and MRI signs
The demographic characteristics of the full analysis set
are summarized in Table 1. The mean age was 74.5 ±
5.1 (SD) years, and there were 58 men and 42 women.
Objective symptoms of severity of 2 or more on the
iNPHGS were noted in 91% for gait disturbance, in 80%
for cognitive impairment, and in 60% for urinary symp-
toms. The combination of symptoms is listed in Table
2. The classical triad was noted in 51%. The mean CSF
pressure on lumbar puncture was 11.9 ± 3.4 cmH2O.
On MRI, the mean Evans’ index was 35.6 ± 4.0%; the
distribution of Evans’ index was illustrated in Figure 4.
Classification of the size of Sylvian fissures is illustrated
in Figure 5A (A-D). Focal dilatation of the cerebral sulci
was noted in 29%, Figure 5A (C) arrow. Overall the Syl-
vian fissures were dilated in 96% (Figure 5B). Mild/mod-
erate and severe white-matter changes were present in
52% and 14%, respectively.
Clinical outcomes
Shunt surgery was successfully completed in all patients.
The mean initial valve pressure was 15.5 ± 4.3 cmH2O,
and was maintained throughout the follow-up period in
46 patients and readjusted in the rest. A favorable out-
come was achieved in 69%, 95% CI: 59.4-77.2% (Figure
6). The distributions of the patients’ functional status at
baseline and one year and their changes are illustrated
in Figure 7A, B. The number of patients without func-
tional impairment (mRS ≤ 1) increased from 7 at base-
line to 44 at one year; the number of independent
patients (mRS ≤ 2 )i n c r e a s e df r o m3 8a tb a s e l i n et o6 8
at one year. Scores on the iNPHGS, TUG, and MMSE
are summarized with each outcome group in Table 3.
All the secondary outcome measures significantly
improved in the analysis of all the patients and in the
analysis of the subgroup with favorable outcome. Even
in the analysis of the subgroup with unfavorable
Figure 3 Two cases excluded by the central MRI review. MRIs of two illustrative cases excluded by the central MRI review board because of
deviation from the pre-set MRI criteria. Note the enlarged subarachnoid spaces (arrow) proportionate to ventriculomegaly indicating brain
atrophy (A), and the open high-convexity and medial subarachnoid spaces (arrow) despite disproportionately expanded ventricles (*) suggesting
chronic occlusive hydrocephalus (B).
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on the TUG. When one point or more decrement on
the total score of the iNPHGS is regarded as clinical
improvement, benefits were noted in 77% of the subjects
at one year after surgery. Shunt responder (improve-
ment ≥ 1 on mRS at any evaluation point in one year)
was noted in 80%, 95% CI: 71.0-86.7% (Figure 6). When
using the iNPHGS as a measure, the response to the
surgery was detected in 89% of the subjects.
Adverse events
Serious adverse events (SAE) were noted in 15 patients
(Figure 6): death occurred in two patients (lung cancer
and pneumonia). Outcome at one year was favourable
in 4 patients and unfavourable in 11 patients (including
the two deaths). Three SAEs were directly related to
surgery or the VP shunt: subdural hematoma requiring
surgery, bowel perforation requiring surgical repair, and
ventricular shunt tube obstruction requiring revision. In
addition, 21 non-serious shunt-related adverse events
were recorded in 20 patients: asymptomatic subdural
effusion on brain imaging in 13 patients and postural
headache in 8 patients, which were successfully con-
trolled in all cases by adjustment of valve pressure.
Discussion
The present study examined both the usefulness of the
M R I - b a s e dd i a g n o s t i cs c h e m ea n dt h eo n e - y e a rb e n e f i -
cial effect of shunt surgery for patients with iNPH. The
diagnosis of iNPH is established in terms of response to
surgery, and the efficacy of surgery depends on diagnos-
tic accuracy. Therefore, there is an interaction between
the accuracy of the diagnostic scheme and the efficacy
of the treatment. Nevertheless, we achieved an improve-
ment rate of 69.0% on daily life activity, which indicates
that all the procedures, including diagnosis and treat-
ment, yield reasonable net benefits. Furthermore, we
proved that the diagnostic scheme has a high positive
predictive value, as the percentage of subjects who were
found at one evaluation point to have responded to the
VP shunt was 80.0% for the whole group, which indi-
cates that MRI-based diagnosis is useful for the diagno-
sis of iNPH.
Assessment of the outcome in iNPH patients is an
important issue; activity of daily life would be more
practical for assessing surgical outcome, and NPH
symptoms would be better for the shunt efficacy. In this
Table 1 Background characteristics for patients in study
Age (years) 74.5 ± 5.1
Sex (male) 58%
Education (years) 10.2 ± 2.9
Systolic pressure (mmHg) 131.0 ± 14.6
Diastolic pressure (mmHg) 75.7 ± 8.9
History of hypertension 60%
History of diabetes 20%
History of a lipid disorder 31%
Smoking status
Currently 10%
Previously 37%
Medications (% present)
L-dopa/dopamine agonist 10%
Donepezil 6%
Antipsychotics 3%
Antidepressants 8%
Antiplatelet agents 18%
Antihypertensives 49%
Antidiabetic agents 13%
Lipid-lowering medication 11%
Data are % present or mean ± standard deviation.
Table 2 Combination of symptoms
Combination of symptoms* No. of patients
Triad 51
Gait and cognitive 23
Gait and urinary 5
Cognitive and urinary 3
Gait only 12
Cognitive only 3
Urinary only 1
Subjective symptoms only 2
*Objective symptoms of score ≥2 on the idiopathic normal pressure
hydrocephalus grading scale (iNPHGS) were listed, and subjective symptoms
imply symptoms of score = 1 on the iNPHGS.
Figure 4 Bar chart showing the distribution of Evans’ index in
the patient population. The mean Evans’ index was 35.6 ± 4.0%
ranging 0.30 to 0.48, which indicated that the dilation of lateral
ventricle in this group was mild to moderate, and marked dilation
was rare.
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Page 6 of 11Figure 5 Dilatation of Sylvian fissures. A) Illustrative MRI sections showing the variable size of Sylvian fissure. A: narrowing, B: normal, C:
mildly-moderately enlarged, D: highly enlarged, A (C): Arrow indicating focal sulcal dilatation. B) Bar chart showing patient distribution of the
four dilation categories described above. The Sylvian fissures were dilated in 96% of patients.
Figure 6 Flow chart showing the outcome for all patients analysed. There were 80 shunt responders with 69 having a favourable outcome.
There were 20 non-responders, 12 of which had some adverse event. Serious adverse events are listed. * Functional improvement (≥ 1
improvement on mRS) at some point during one year. † Functional improvement (≥ 1 improvement on mRS) at one year. mRS: modified Rankin
Scale. SAE: Serious adverse event. AE: Adverse event.
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level improvement on mRS. The mRS is the most popu-
lar assessment of global outcome in stroke [16], and has
also been used to measure disability in other non-stroke
neurological diseases [21-23], including iNPH [24,25].
As the grading definitions of the mRS are very broad
classifications of disability, only sizable changes can be
detected [22]. Moreover, inter-rater reliability may be an
important source of error with the mRS. However, in
this study, improvements were detected in a large pro-
portion of the subjects, suggesting a significant treat-
ment effect. The improvements were also confirmed on
all the other scales used. In particular, the iNPHGS,
which is a valid and reliable scale specific for iNPH [14],
provided a very sensitive means of detecting change;
this scale detected improvements in 77.0%. The timed
“Up & Go” test also detected improvements even in the
subgroup with unfavorable outcome, where no improve-
ment or deterioration was recorded on the less sensitive
mRS. Therefore, if the low sensitivity of the mRS is
taken into consideration, the outcome in this study is
acceptable.
Serious adverse events occurred in 15 patients, and all
but three of these were unrelated to the operation or VP
shunt. Considering the subjects’ mean age of 75 years,
vascular events, malignancies, infections, and fractures
were not uncommon. Outcomes for those who experi-
enced an SAE were generally unfavorable, as would be
expected. In addition, asymptomatic subdural effusion (n
= 13) and orthostatic headache (n = 8) were reported as
non-serious shunt-related adverse events. These were
controlled well by adjustment of valve pressure [24].
Although a considerable number of retrospective case
series have been published [26-28], prospective studies
using standardized validated outcome measures, which
are comparable to the present study, are very scarce. The
Dutch NPH study group, in their prospective study,
treated 101 patients with iNPH with VP shunt by using
fixed pressure valves, and yielded a one-year improve-
ment rate of 59% based on mRS [24]. The group reported
quite a high incidence of shunt-related adverse events:
transient and persistent subdural effusion in 53% of
Figure 7 Bar charts of patients’ functional status based on the modified Rankin scale (mRS). A: Distribution at baseline and one year.
B: Change between baseline and one year.
Table 3 Changes of outcome measures with each
outcome group.
Baseline 12 months p value*
INPHGS gait score
All patients 2 (2.3-2.6) 1 (1.2-1.7) < 0.001
Favorable outcome 2 (2.3-2.6) 1 (0.8-1.3) < 0.001
Unfavorable outcome 2 (2.1-2.7) 2 (1.9-2.8) ns
iNPHGS cognitive score
All patients 2 (2.1-2.4) 1 (1.3-1.7) < 0.001
Favorable outcome 2 (2.0-2.5) 1 (1.0-1.5) < 0.001
Unfavorable outcome 2 (1.8-2.6) 2 (1.6-2.4) ns
iNPHGS urinary score
All patients 2 (1.7-2.2) 1 (0.8-1.3) < 0.001
Favorable outcome 2 (1.5-2.1) 1 (0.5-0.9) < 0.001
Unfavorable outcome 2 (1.8-2.8) 2 (1.4-2.4) ns
iNPHGS total score
All patients 6 (6.1-7.1) 4 (3.4-4.6) < 0.001
Favorable outcome 6 (5.9-7.1) 2 (2.4-3.6) < 0.001
Unfavorable outcome 6 (5.9-7.9) 5 (5.1-7.5) ns
Timed “up & go” test (seconds)
All patients 20.5 (16-30) 14 (11-20) < 0.001
Favorable outcome 20 (16.5-28) 13 (10-17) < 0.001
Unfavorable outcome 22 (15-41) 20 (13-33) 0.004
MMSE
All patients 23 (16.3-26) 25 (20.3-28) < 0.001
Favorable outcome 23 (15.5-26) 25 (21.5-28) < 0.001
Unfavorable outcome 23 (17-25) 24 (16-27) ns
Data are median (75th percentile).
*All p values were obtained using Wilcoxon test. ns: not significant.
iNPHGS: Idiopathic Normal-Pressure Hydrocephalus Grading Scale, MMSE:Mini-
Mental State Examination.
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as well as extraperitoneal displacement, ventricular dis-
placement, disconnection, and infection of the shunt
required surgical treatment [25]. Subdural effusion/
hematoma was twice as frequent with low-pressure (3-5
cmH2O) valves than with medium-pressure (9-11
cmH2O) valves [25]. Compared with the Dutch study, the
use of the programmable valve and the relatively high
average initial valve pressure of 15.5 cmH2O based on
the pressure-setting scheme in our trial favoured a low
incidence of serious CSF over-drainage without affecting
shunt effectiveness. Although our results suggest the
advantage of CHPV in comparison with fixed-valve shunt
systems, head-to-head comparison is needed in rando-
mized controlled trials to draw a conclusion.
Kitagaki et al., based on their case-control study invol-
ving volumetry of CSF spaces, pointed out that tight
high-convexity and subarachnoid spaces support the
diagnosis of iNPH [10]. The present study confirmed
the diagnostic value of these MRI findings. The Dutch
iNPH study group used the sum of the four largest con-
vexity sulci being less than 25 mm on CT as a criterion
of tight convexity subarachnoid spaces [24], which is
partially compatible with our study. However, axial CT
slices are inferior to coronal MRI sections in viewing
the high-convexity region. Axial and coronal MRIs accu-
rately detect narrow sulci at the high convexity and
midline, which accurately predicts iNPH [29]. Kitagaki
et al. also reported that distended basal cisterns and Syl-
vian fissures and focally dilated sulci are features of
iNPH [10]. Recently, Ishii et al., in a controlled study
using a voxel-based morphometry technique, demon-
strated densely compacted parietal gyri in patients with
iNPH, as well as ventricular enlargement and Sylvian
fissure dilatation [30]. Whereas, in the present trial, can-
didates were selected only on the basis of ventriculome-
galy and tight high-convexity and medial subarachnoid
spaces on coronal MRIs, enlarged Sylvian fissures and
focally dilated sulci were found in 96% and 29%, respec-
tively. The present prospective cohort study showed
enlargement of the Sylvian fissures in the vast majority
of patients with iNPH. Enlargement of the Sylvian fis-
sures by retention of CSF is another feature of iNPH.
Thus, CSF distributes disproportionately between the
superior and inferior subarachnoid spaces. It is morpho-
logically distinguishable from communicating hydroce-
phalus secondary to subarachnoid hemorrhage or
meningitis (secondary NPH) and non-communicating
hydrocephalus. We propose the generic term dispropor-
tionately enlarged subarachnoid-space hydrocephalus
(DESH) for this type of hydrocephalus. The clinical sig-
nificance of DESH in communicating hydrocephalus is
the presence of enlargement subarachnoid spaces speci-
fically in their inferior parts. Enlarged ventricles and
large Sylvian fissures in combination with tight high-
convexity subarachnoid space should not be misinter-
preted as cerebral atrophy.
The present study had several notable limitations that
require discussion. The most critical issue is that it
lacked a control group. However, as iNPH is a progres-
sive disease, management without surgery would not be
allowed for ethical reasons. Another crucial issue is
related to the unblinded design of the study: the neuro-
surgeons and neurologists in charge of the patients’ care
and evaluation were aware of the treatment, which
represents a possible source of performance and detec-
tion bias. Thirdly, the central MRI review committee
excluded patients who did not fulfil the MRI criteria,
which is a source of selection bias. Further, any patients
with the MRI criteria but without the symptomatic triad
and any patients with the symptoms but without the
MRI criteria were not considered. These issues should
be taken into consideration before the findings are gen-
eralized. Also, in this study, the roles of several diagnos-
tic measures, including the tap test, CSF measurement,
and CT cisternography, were examined, and the data
r e l a t e dt ot h el o n g - t e r mm a n a g e m e n to ft h es h u n ts y s -
tem were collected. Information about the additional
measures and procedures will be reported in a later
paper.
Conclusions
Our study demonstrated that the MRI-based scheme
supports the diagnosis of iNPH. The MRI features of
DESH, i.e., tight high-convexity and medial subarach-
noid spaces and enlarged Sylvian fissure associated with
ventriculomegaly are useful for the diagnosis of iNPH.
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